ProCE Banner Activity

Nuevos datos sobre inhibidores de QBT para la LLC y el LCM: expertos hablan sobre la EHA 2022

Clinical Thought

En este comentario, 2 expertos hablan sobre las implicaciones de los datos de ensayos clínicos presentados en la EHA 2022 sobre los tratamientos basados en inhibidores de la TQB para pacientes con leucemia linfocítica crónica y linfoma de células del manto.

Released: August 15, 2022

Expiration: August 14, 2023

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Lydia Scarfò

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Othman Al-Sawaf, MD: honoraria: AbbVie, Adaptive Biotechnologies, Ascentage, AstraZeneca, BeiGene, Gilead Sciences, Janssen-Cilag, Roche; consultant/advisor: AbbVie, Gilead Sciences, Janssen-Cilag, Roche; researcher (institution): AbbVie, BeiGene, Janssen/Pharmacyclics, Roche; travel/accommodations/expenses: AbbVie, Gilead Sciences, Janssen-Cilag, Roche.

Lydia Scarfò, MD

Assistant Professor
Internal Medicine
Università Vita-Salute San Raffaele
Consultant Hematologist
Strategic Research Program on CLL
Milan, Italy

Lydia Scarfò, MD: honoraria: AbbVie, AstraZeneca, BeiGene, Janssen, Octapharma; travel grants: BeiGene, Janssen.